Barclays
NTLA icon

Barclays’s Intellia Therapeutics NTLA Stock Holding History

Barclays’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-43,000
Closed -$1.18M – 5171
2024
Q1 		$1.18M Sell
43,000
-29,200
-40% -$811K ﹤0.01% 2984
2023
Q4 		$2.2M Buy
+72,200
New +$2.08M ﹤0.01% 2841

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays's NTLA Position: Q1 2026 in Review

Barclays reduced its Intellia Therapeutics (NTLA) stake by 71% in Q1 2026, selling an estimated $4.64M and leaving 147,242 shares worth $1.89M. The position accounts for ﹤0.01% of the portfolio, ranked #2387.

Barclays first reported a position in NTLA in Q2 2016 and has held it in 40 quarters since. The position peaked at $16.4M in Q4 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Barclays held 147,242 shares of Intellia Therapeutics worth $1.89M as of Q1 2026.
  • Barclays sold 363,998 Intellia Therapeutics shares in Q1 2026, an estimated $4.64M.
  • Intellia Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2387 holding.
  • Barclays first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 40 quarters since.
  • Barclays's Intellia Therapeutics position peaked at $16.4M in Q4 2021.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.